Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19392403 | 0.93 | ALDH1A1 (0.60) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL7621847 | 0.89 | ALDH1A1 (0.75) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL29909105 | 0.89 | MMP2 (0.65) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL812738 | 0.88 | ALDH1A1 (0.75) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL8349568 | 0.87 | ALDH1A1 (0.79) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL4060764 | 0.86 | ALDH1A1 (0.79) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL9121912 | 0.86 | CYP2C19 (0.69) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL7623885 | 0.86 | CYP2C19 (0.73) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL27739300 | 0.86 | ALDH1A1 (0.57) | ALDH1A1PKMLMNASMN1; SMN2KDM4E | |
| SCHEMBL8595157 | 0.85 | ALDH1A1 (0.82) | ALDH1A1PKMLMNASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563720-A2 | ELECTROLYTIC COPPER FOIL HAVING DOUBLE-SIDED LOOSE STRUCTURE, PREPARATION METHOD AND APPLICATION THEREOF | Jiujiang Defu Tech Co Ltd (CN) | 2025-06-04 | — | — | EP | claimed |
| CN-117661046-A | Electrolytic copper foil with double-sided loose structure and preparation method and application thereof | 九江德福科技股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-114249980-B | Glass fiber reinforced polyamide material for plastic high-pressure water gun and preparation method thereof | 上海聚威新材料股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-114249979-B | Polyamide composition with NTC effect and preparation method thereof | 金发科技股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114106669-B | Curing agent based on N-hydroxyethyl benzene sulfonamide compound and preparation method and application thereof | 镇江牛盾新材料科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-114249980-A | Glass fiber reinforced polyamide material for plastic high-pressure water gun and preparation method thereof | 上海聚威新材料股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114249979-A | Polyamide composition with NTC effect and preparation method thereof | 金发科技股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| WO-2022057210-A1 | POLYAMIDE COMPOSITION HAVING NTC EFFECT AND PREPARATION METHOD THEREFOR | 金发科技股份有限公司 | 2022-03-24 | — | — | WO | claimed |
| CN-114106669-A | Curing agent based on N-hydroxyethyl benzene sulfonamide compound and preparation method and application thereof | 镇江牛盾新材料科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-7700654-B2 | Isolation of N-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of N-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2010-04-20 | — | — | US | claimed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| EP-0929603-B1 | PLASTICISED POLYMER COMPOSITIONS | UCB SA (BE) | 2003-12-03 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| US-6624218-B2 | A blend comprising aromatic plasticizer benzenesulphonamides and semi-crystalline polymer; exhibits a processing temperature equal to or greater than 220 degrees C.; melt material for extrusion and injection molding | UCB, S.A. (BE) | 2003-09-23 | — | — | US | claimed |
| US-20020165301-A1 | Plasticized polymer compositions | UCB, S.A. | 2002-11-07 | — | — | US | claimed |
| EP-0929603-A1 | PLASTICISED POLYMER COMPOSITIONS | UCB, S.A. (BE) | 1999-07-21 | — | — | EP | claimed |
| WO-1998014513-A1 | PLASTICISED POLYMER COMPOSITIONS | UCB, S.A. (BE) | 1998-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | ALDH1A1 4524/4885PKM 805/4885LMNA 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.